Applied Filters
Got a patent, now where to validate?
For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.
Patent filing strategies for pharma startups
Patents are a key asset for pharmaceutical startups, but where are they choosing to file? Jian Siang Poh and Angus Fairbairn of Marks & Clerk report.
The importance of Minerva Surgical v Hologic
A decision by the Supreme Court over the assignor estoppel doctrine could have far-reaching implications for patent law, argue Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks of Snell & Wilmer.
What 2020 means for the life sciences
Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.
Pricing, patents and the PMPRB in Canada
Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.
The doctrine of equivalents in the medtech arena
The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.
Why Santen ends Neurim-style SPCs
In a boost for generic pharma companies, a U-turn by the EU’s highest court removed protection for repurposed active substances, as Robert Stephen and Gareth Morgan of CMS Cameron McKenna Nabarro Olswang explain.
The right recipe for the repurposing omelette
Big Pharma is looking for solutions to the COVID-19 pandemic wherever it can find them, so drug repurposing is more important than ever, as research lawyers Jakob Wested and John Liddicoat argue.
No SPC crown for Royalty Pharma
An attempt to obtain a supplementary protection certificate ended up raising the bar to achieving this coveted IP, as Joel Beevers and Michael Pears of Potter Clarkson explain.
Could good intentions lead to future danger?
The rush to open access to IP-protected tech, medicines and devices in the fight against COVID-19 could cause problems later, argues MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch.
